NCT01499732已完成不适用
An Exploratory Trial to Evaluate Premature Endothelial Dysfunction, as Measured by Positron Emission Tomography (PET) Scan With Cold Pressor Test (CPT), in Patients With Early Rheumatoid Arthritis (RA) Compared to Patients With Established RA, and Normal Subjects. Additionally, the Relationship Between the PET Scan Findings and the Inflammatory, Cardiovascular Risk, and Endothelial Dysfunction Biomarkers Will be Analyzed
Orrin M Troum, M.D. and Medical Associates1 个研究点 分布在 1 个国家实际入组 15 人开始时间: 2011年12月最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- To evalute the presence of endothelial dysfunction in patients with rheumatoid arthritis utilizing PET/CT scan with cold pressor test.
研究概览
简要总结
Premature Endothelial Dysfunction is present in patients with early rheumatoid arthritis.
研究设计
- 研究类型
- 观察性
- 观察模型
- 队列研究
- 时间视角
- 前瞻性
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- Group 1
- Subjects currently experiencing active early RA (duration of symptoms ≤ 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening.
- Subjects with early RA must be drug naïve (no prior treatment with traditional disease-modifying antirheumatic drugs (DMARDs), or biologic response modifying agents). Group 2
- Subjects currently experiencing active established RA (duration of symptoms ≥ 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening.
- Subjects with active established RA currently receiving methotrexate (MTX), must have received it for at least 12 weeks, and at a stable dose (≥15mg/week) for at least 6 weeks prior to screening. They must be biologic drug naïve. These subjects must receive at least 5 mg oral folic acid weekly.
- Subjects diagnosed with RA must be seropositive with documented rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti CCP) positivity. If a documented history of RF or anti CCP positivity is not available, RF and anti CCP titers will be obtained at screening Group 3
- Healthy subjects without RA.
- All subjects must have sitting diastolic BP ≤90 mm Hg and/or sitting systolic BP ≤ 140 at screening
- Subjects must have fasting plasma glucose (FPG) of ≤ 100 mg/dL.
- If subjects with established RA are receiving an oral corticosteroid, the dose must be ≤7 mg/day prednisone (or equivalent) and stable for at least 28 days prior to screening.
- Subjects able and willing to give written informed consent and comply with the requirements of the study protocol. Informed consent must be obtained prior to any study-related procedures. A copy of the signed informed consent form must be given to the subject
- Patients must have a BMI of less than 42
排除标准
- Major surgery (including joint surgery) within 8 weeks prior to screening.
- Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis, or significant systemic involvement secondary to RA (vasculitis, pulmonary fibrosis or Felty's syndrome). Prior history of or current inflammatory joint disease other than RA (gout, Lyme disease, seronegative spondyloarthropathy including reactive arthritis and psoriatic arthritis)
- Functional class IV as defined by ACR Classification of Functional Status in RA
- Current treatment with any traditional DMARDs other than MTX within 4 weeks before the screening visit (For subjects with established RA). Current or prior use of Leflunomide will be exclusionary.
- Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before screening
- Exposure to any Biologic Response Modifying Agent for RA
- Intraarticular or parenteral corticosteroids within 6 weeks prior to screening (For subjects with established RA)
- Exclusionary laboratory: Serum creatinine >2 mg/dL, ALT or AST > 2.0 x ULN, total bilirubin > 2.0 x ULN, platelet count <100 x 10⁹ /L, hemoglobin < 8.5 g/dL, WBC count < 1,000/mm³ , absolute neutrophil count < 1,000/ mm³, absolute lymphocyte count < 500/mm³, triglycerides >400 mg/dL, Serum potassium <3.5 or >5.5 mEq /L without medication, serum albumin <2.5 g/dL, Gamma GT 3.0 x UNL
- Smokers (use of tobacco products in the recent past < 6 months). Urine cotinine levels will be measured during screening for all subjects. Smokers will be defined as any subject who reports cigarette use or has a urine cotinine greater than 200 ng/mL.
- Pregnant women or nursing mothers
- Females of child bearing potential who are not using reliable means of contraception
- Evidence of serious uncontrolled concomitant cardiovascular (including known CAD, HTN, or hyperlipidemia), nervous system, pulmonary, renal, hepatic, endocrine or GI disease.
- Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel syndrome, where flares are commonly treated with corticosteroids.
- History or presence of severe bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
- History of cardiovascular abnormalities including myocardial infarction, angina pectoris, hypertensive encephalopathy, stroke, transient ischemic attack, valvular heart disease, ventricular arrhythmia A-V block, atrial fibrillation or cardiac revascularization/angioplasty. Symptoms or clinical evidence of congestive heart failure or known left ventricular ejection fraction < 40%.
- Medical history of clinically significant ECG abnormalities, including history of a prolonged QT-interval syndrome.
- History of autonomic dysfunction
- Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections such as atypical mycobacterial disease, hepatitis B and C, HIV, herpes zoster, or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.
- Any malignancy except for skin cancer (basal cell or squamous cell) diagnosed within the previous 5 years
研究组 & 干预措施
Early Rheumatoid Arthritis
Subjects currently experiencing active early rheumatoid arthritis (duration of symptoms < or = 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening. Must be drug naive (no prior treatment with traditional disease-modifying antirrheumatic drugs (DMARDs), or biologic response modifying agents)
干预措施: Early Rheumatoid Arthritis
Healthy subjects without rheumatoid arthritis
Healthy subjects without rheumatoid arthritis
干预措施: Healthy subjects without rheumatoid arthritis
Established Rheumatoid Arthritis
Subjects currently experiencing active established rheumatoid arthritis (duration fo symptoms > or = 2 years) according to the 2010 ACR/EULAR criteria at screening. Subjects with active established RA currently receiving methotrexate, must have received it for at least 12 weeks, and at a stable dose (> or = 15 mg/week) for at least 6 weeks prior to screening. They must be biologic naive, and must recieve at least 5mg oral folic acid weekly
干预措施: Established Rheumatoid Arthritis
结局指标
主要结局
To evalute the presence of endothelial dysfunction in patients with rheumatoid arthritis utilizing PET/CT scan with cold pressor test.
时间窗: 5 months
Endothelial dysfunction will be defined as myocardial blood flow (MBF)during cold pressor test (CPT)of less than or equal to 40%
次要结局
- To evaluate the relationship between PET Scan findings and biomarkers (inflammatory, cardiovascular risk and endothelial dysfunction), and outcome measures(5 months)
研究者
研究点 (1)
Loading locations...
标识符
- NCT 编号
- NCT01499732
- 其他研究编号
- IM101-320
日期
- 首次提交
- (14年前)
- 首次发布
- (14年前)
- 主要完成日期
- 研究完成日期
- 最近核实
- 最近更新
- (13年前)
监管与共享
- FDA 监管药物
- 否
- 是否有结果
- 否
相似试验
Unknown
不适用
同适应症Factors of ILD in Newly Diagnosed Rheumatoid ArthritisRheumatoid ArthritisNCT04002765Cliniques universitaires Saint-Luc- Université Catholique de Louvain300
Unknown
不适用
同适应症Role of Greyscale and Power Doppler Sonography in Therapy Monitoring in Early Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT00854243Cairo University20
Unknown
不适用
同适应症INCMNSZ - Rheumatoid Arthritis CohortEarly Rheumatoid ArthritisRheumatoid ArthritisNCT03389711National Institute of Medical Sciences and Nutrition, Salvador Zubiran237
已完成
不适用
同适应症Use of Thermal and 3D Imaging to Quantify ArthritisJuvenile Rheumatoid ArthritisRheumatoid ArthritisNCT01044823University of Pittsburgh157
招募中
2 期
同适应症Desloratadine as Adjunct Therapy for Rheumatoid ArthritisRheumatoid ArthritisRheumatoid Arthritis (RA)NCT07632872Horus University60